RxDoctor Payments Data

Lauren Snapp, NP

Family · Johnson City, TNNPI 1932582012

Payments from drug & device makers

$912in general payments, 2019–2025

Across 28 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$140
  • Novo Nordisk$116
  • Inspire Medical Systems, Inc.$113
  • Sanofi-aventis U.S. LLC$101
  • Gilead$101
  • Abbott$89
  • plus $252 from 5 others

What the payments were for

  • Food & beverage$912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912 in reported general payments places this provider in the 60th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$47,691
Medicare patients
251
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$36,827
OzempicSemaglutide22$22,482
XareltoRivaroxaban16$13,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,289
Nurtec OdtRimegepant Sulfate11$11,345
Bydureon BciseExenatide Microspheres12$10,030
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,075
Omeprazole78$1,813
SynthroidLevothyroxine Sodium15$1,756
Levothyroxine Sodium149$1,252
Gabapentin67$1,195
Metoprolol Succinate57$1,069
Midodrine Hcl11$1,057
Famotidine46$1,036
Rosuvastatin Calcium110$1,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$22,48222 claims
Johnson & JohnsonXarelto$15$13,51316 claims
AbbVieSynthroid$57$1,75615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →